- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
Share warrant program fully subscribed
XVIVO Perfusion AB's share warrant program 2016/2018 is fully subscribed. A total of 212,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2018 the right to subscribe for one new share at a price of SEK 90.22.
The annual shareholder meeting May 3, 2016 approved the warrant program of a maximum of 212,000 warrants to be offered to employees in XVIVO Perfusion. Upon full exercise of the warrants, the share capital increase is around SEK 5,500 corresponding to a dilution of about 0.9 percent of the total number of shares and votes.
Magnus Nilsson, CEO of XVIVO Perfusion: “The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals.”
July 8, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on July 8, 2016 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
